An open-label, phase 1 trial with expansion cohort of botensilimab (AGEN1181) + balstilimab (AGEN2034) + nab-paclitaxel + gemcitabine + cisplatin + chloroquine + celecoxib in adult patients with previously untreated metastatic pancreatic cancer.

Authors: Erkut H. Borazanci, Gayle S. Jameson, Brandi Carter, Lu Zhao, Haiyong Han, Derek Cridebring, Michael S. Gordon, Daniel D. Von Hoff

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4234

Source: Full article

TPS4234